Komuta Mina
Department of Pathology, International University of Health and Welfare, School of Medicine, Chiba 286-8520, Japan.
Department of Pathology, School of Medicine, Keio University, Tokyo 160-8582, Japan.
Cancers (Basel). 2021 Jun 8;13(12):2871. doi: 10.3390/cancers13122871.
Primary liver cancers (PLCs) mainly comprise hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and cHCC-CCA. Combined HCC-CCA and small duct type iCCA show similar clinical presentations, and their histological features are more complex than seen in HCC. Therefore, while their treatment strategy differs, it is difficult to properly diagnose these tumors. Currently, HCC is the only tumor that can be treated by liver transplantation. In addition, small duct type iCCA harbors IDH1/2 mutations and FGFR2 fusions, which can be used for targeted therapy. Thus, improving diagnostic accuracy is crucial. A further point to note is that PLCs often present as multiple liver tumors, and they can be a combination of different types of PLCs or HCCs. In the case of HCCs, two different scenarios are possible, namely intrahepatic metastasis, or multicentric occurrence. Therefore, it is essential to characterize the type of multiple liver tumors. This review aims to clarify the pathological features of HCC, iCCA and cHCC-CCA, including their diagnostic pitfalls and clinical relevance. It is designed to be of use to clinicians who are dealing with PLCs, to provide a better understanding of the pathology of these tumors, and to enable a more accurate diagnosis and optimal treatment choice.
原发性肝癌(PLC)主要包括肝细胞癌(HCC)、肝内胆管癌(iCCA)和肝细胞-胆管癌(cHCC-CCA)。HCC-CCA合并型和小胆管型iCCA临床表现相似,其组织学特征比HCC更为复杂。因此,尽管它们的治疗策略不同,但对这些肿瘤进行准确诊断仍很困难。目前,HCC是唯一可通过肝移植治疗的肿瘤。此外,小胆管型iCCA存在异柠檬酸脱氢酶1/2(IDH1/2)突变和纤维母细胞生长因子受体2(FGFR2)融合,可用于靶向治疗。因此,提高诊断准确性至关重要。另一个需要注意的要点是,PLC常表现为多发肝肿瘤,它们可以是不同类型的PLC或HCC的组合。对于HCC,可能存在两种不同情况,即肝内转移或多中心发生。因此,明确多发肝肿瘤的类型至关重要。本综述旨在阐明HCC、iCCA和cHCC-CCA的病理特征,包括其诊断陷阱及临床相关性。其目的是为处理PLC的临床医生提供帮助,以便更好地理解这些肿瘤的病理学,从而实现更准确的诊断和最佳的治疗选择。